signaling in mouse brain development 13 , and may be critical for pancreatic cancer cell proliferation and VEGF-A induced pancreatic tumor angiogenic response 8, 9 . The proteoglycan GPC1, GPI-anchored to the cell surface, acts as a co-receptor for several heparin binding growth factors, thereby implicating it in promoting tumor progression [9] [10] [11] [12] 14 .
In patients with pancreatic cancer, we described the enrichment of GPC1 ( Table 1) . Although the methodologies differed in each study, GPC1 was indeed elevated in exosomes of patients with cancer.
Here we report on the use of three anti-Glypican 1 antibodies for the specific detection of GPC1 + exosomes in the circulation of pancreas cancer patients (n=10) compared to healthy donors (n=9) and benign pancreatic diseases (BPD, n=2) using flow cytometry as a readout. The ThermoFisher antibody used in our initial report 1 (PA5-28055) is commercially available. We also utilized antibody SAB2700282 from Sigma, and MAB8351 from Abnova. Both ThermoFisher and Sigma described the immunogen as a recombinant fragment of human GPC1 corresponding to a region within amino acids 200 and 558. Abnova describes the immunogen as recombinant protein corresponding to full length human GPC1. We report on the highly reproducible and strong correlation between samples evaluated with each of these antibodies ( Figure 1A-B) . Notably, all 10 patients with PDAC showed elevated circulating GPC1 + exosomes bound-beads, in contrast with the 9 healthy donors and 2 BPD samples ( Figure 1A , Table 2 ). We also proceeded with analyses using the ThermoFisher anti-GPC1 antibody PA5-24972, however we noted this antibody did not reproduce our initial findings (Table 3) . Further, when exosomes were collected using isolation kits rather than the described ultracentrifugation procedure, the accuracy of detection was lost. Therefore, ultracentrifugation for exosomes enrichment is required to evaluate GPC1 on exosomes.
In an effort to engage the scientific community in evaluating the utility of GPC1 + exosomes in early detection or monitoring of pancreas cancer patients, we provide a detailed methodology, in a step-wise manner, to accompany the findings reported therein (Table 4) .
We look forward to a productive scientific discourse on our ongoing efforts to identify GPC1 on cancer exosomes using different methods and antibodies.
Methods
We provide a detailed protocol in Table 4 comparing the three anti-GPC1 antibodies listed. When the Abnova antibody was used, n=6 samples were analyzed (see Table 2 ). B. Linear regression analysis between % of GPC1 + circulating exosomes on beads obtained using the ThermoFisher PA5-28055 and Sigma SAB2700282 antibodies. 
References:

